Rob Hershberg, HilleVax CEO

One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

Tachi is gone, but his lega­cy biotechs are con­tin­u­ing to make news.

This morn­ing it’s the new­ly born Hill­e­Vax — a cre­ation of Take­da and Fra­zier Health­care Part­ners, where Tachi Ya­ma­da was re­spec­tive­ly CSO and a long­time part­ner — that’s tak­ing a big step for­ward to late-stage test­ing of its norovirus vac­cine with a $135 mil­lion crossover megaraise. Hill­e­Vax CEO Rob Her­sh­berg — who be­came Cel­gene CSO and BD chief af­ter they bought out his ear­li­er start­up, Ven­tiRx — is at the helm. And the start­up crew has at­tract­ed some star tal­ent to the board of what will re­main a rel­a­tive­ly small, close­ly fo­cused biotech team look­ing to take the long, tra­di­tion­al route to a vac­cine ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.